South Korea
· Delayed Price · Currency is KRW ABION Company Description
ABION Inc. operates as a pharmaceutical biotech Company in South Korea and internationally.
The company develops anticancer therapeutic drugs, such as ABN401, a tyrosine kinase inhibitor that is in Phase II clinical trials for treating non-small cell lung cancer, as well as in Phase I clinical trial for breast cancer; ABN501, a human monoclonal antibody that targets claudin 3 for treating solid cancers; ABN201, an antibody cytokine fusion protein to treat solid cancers; and ABN101, a dry powder inhaler as a prophylactic treatment for various respiratory viruses.
It is also developing ABN701 for SEBI infectious diseases; and ABN 901, ABN 902, and ABN 903 for infectious diseases related to biological disasters.
Abion Inc. was founded in 2007 and is based in Seoul, South Korea.
| Country | South Korea |
| Founded | 2007 |
| Industry | Biological Products, Except Diagnostic Substances |
| Employees | 38 |
| CEO | Young-Gi Shin |
Contact Details
Address: Hanhwa Biz Metro Bldg Seoul, 08394 South Korea | |
| Phone | 82 2 6006 7657 |
| Website | abionbio.com |
Stock Details
| Ticker Symbol | 203400 |
| Exchange | KOSDAQ |
| Fiscal Year | January - December |
| Reporting Currency | KRW |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Young-Gi Shin | Chief Executive Officer |